| |
HR
|
p value
|
HR
|
p value
|
HR
|
p value
|
|---|
|
Early administration of TLV
|
1.210
|
< 0.001
|
1.200
|
< 0.001
|
1.190
|
< 0.001
|
|
Age (years)
|
0.998
|
0.904
| | | | |
|
BMI (kg/m2)
|
0.925
|
0.104
| | | | |
|
Sex (men)
|
0.960
|
0.918
| | | | |
|
Clinical scenario 1
| | |
1.310
|
0.595
| | |
|
Systolic BP (mm Hg)
| | |
1.000
|
0.919
| | |
|
NHYA
| | | | |
2.040
|
0.159
|
|
BNP (pg/dl)
| | | | |
1.000
|
0.588
|
|
Hemoglobin (g/dl)
| | | | |
0.917
|
0.205
|
- TLV: tolvaptan, BMI: body mass index, BP: blood pressure, NHYA: New York Heart Association Classification, BNP: brain natriuretic peptide. The multivariate analysis was performed applying Cox proportional hazards models
